{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000030","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.620170+00:00","generated_at":"2026-06-05T22:46:02.953549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance","bullets":["Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.","GAAP net income $15.0M (diluted EPS $0.11) down 70% YoY due to acquisition costs; non-GAAP diluted EPS $0.60 (+2.1%).","Full year 2023 net sales $1,568.5M (+53.3%); GAAP EPS $1.07; non-GAAP EPS $2.32.","Legacy Globus organic revenue grew 10.8% in Q4 and 12.8% for full year vs prior year.","FY2024 guidance reaffirmed: net sales $2.450B-$2.475B; non-GAAP EPS $2.68-$2.70."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000030","json":"https://secwatch.observer/filing/0001562762-24-000030.json","markdown":"https://secwatch.observer/filing/0001562762-24-000030.md","text":"https://secwatch.observer/filing/0001562762-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/gmed-20240220x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:46:02.953549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7126d0177759b7ff6e1d43814f412ad86057e177","claim":"GLOBUS MEDICAL INC reported the fourth quarter ended December 31, 2023 results: revenue $ 616.5 million, net income $ 15.0 million, EPS $0.11.","evidence_excerpt":"Worldwide net sales for the fourth quarter were $ 616.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$ 616.5 million"},{"label":"Net income","value":"$ 15.0 million"},{"label":"EPS","value":"$0.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"da8cc65b443401edcb7187d2ec35d834e0127c9f","claim":"GLOBUS MEDICAL INC reported the fiscal year ended December 31, 2023 results: revenue $ 1,568.5 million, net income $ 122.9 million, EPS $1.07. Guidance reaffirmed.","evidence_excerpt":"EPS ”) was $0. 11 and non-GAAP diluted EPS was $0. 60 · Non-GAAP adjusted EBITDA was $ 1 70.0 million, or 27. 6 % of net sales  Full Year 20 2 3 : · Worldwide net sales were $ 1,568.5 million , an increase of 53.3% on an actual and constant currency basis · GAAP n et income for the year was $ 122.9 million · GAAP d iluted EPS was $ 1.07 and n on-GAAP diluted EPS was $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000030/0001562762-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$ 1,568.5 million"},{"label":"Net income","value":"$ 122.9 million"},{"label":"EPS","value":"$1.07"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}